bezacitinib   Click here for help

GtoPdb Ligand ID: 14658

Synonyms: bewintinib | bonretinib | compound 1a [WO2017129116] | OB-756 | OB756
Approved drug Immunopharmacology Ligand
bezacitinib is an approved drug
Compound class: Synthetic organic
Comment: Bezacitinib (OB756) is an orally bioavailable selective Janus kinase 2 (JAK2) inhibitor [1,3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 121.9
Molecular weight 399.47
XLogP 0.25
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCS(=O)(=O)N1CCC(CC#N)(CC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4
Isomeric SMILES C1C(N2C=C(C=3N=CN=C4NC=CC34)C=N2)(CC#N)CCN(S(CC)(=O)=O)C1
InChI InChI=1S/C18H21N7O2S/c1-2-28(26,27)24-9-5-18(4-7-19,6-10-24)25-12-14(11-23-25)16-15-3-8-20-17(15)22-13-21-16/h3,8,11-13H,2,4-6,9-10H2,1H3,(H,20,21,22)
InChI Key FMPVHEWUXRWOKK-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Huang J, Li R, Gong T, Guo P, Shou L, Zhou H, Jiao Z, Zhang F, Liu Q, Zhao L et al.. (2025)
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.
Cancer, 131 (20): e70101. [PMID:41060136]
2. Yin J, Lu Y, Li B. (2017)
Pyrrolopyrimidine five-membered azacyclic derivative and application thereof.
Patent number: WO2017129116A1. Assignee: HANGZHOU HUADONG MEDICINE GROUP PHARMACEUTICAL RESEARCH INSTITUTE Co Ltd. Priority date: 25/01/2017. Publication date: 03/08/2017.
3. Zhuge D, Chen N, Zhao M, Zheng M, Yin J, Lu Y. (2022)
Compounds for the treatment of lupus erythematosus.
Patent number: CN114681461A. Assignee: Hangzhou Bangshun Pharmaceutical Co ltd. Priority date: 28/12/2021. Publication date: 01/07/2022.